Preclinical PAH studies in Sugen 5416/hypoxia (SuHx) and monocrotaline (MCT) exposed rats demonstrated that inhibition of TGFβ signalling via ALK5 prevents the progression and development of PAH [3–5]. The gene discussed is TGFBR1; the disease is pulmonary arterial hypertension.